Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 62, Issue 4, 2015, Pages 629-636

  Stieglitz, Elliot ^a   Ward, Ashley F ^a   Gerbing, Robert B ^b   Alonzo, Todd A ^b   Arceci, Robert J ^c   Liu, Y Lucy ^d   Emanuel, Peter D ^d   Widemann, Brigitte C ^e   Cheng, Jennifer W ^f   Jayaprakash, Nalini ^e   Balis, Frank M ^g   Castleberry, Robert P ^h   Bunin, Nancy J ^g   Loh, Mignon L ^a   Cooper, Todd M ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f PENNSYLVANIA HOSPITAL   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

13 cis retinoic acid; Farnesyl transferase inhibitor; Hematopoietic stem cell transplant; Juvenile myelomonocytic leukemia; Tipifarnib

Indexed keywords

CYTARABINE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; ISOTRETINOIN; TIPIFARNIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; QUINOLONE DERIVATIVE; SQUALENE SYNTHASE; VIDARABINE;

ACUTE TOXICITY; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE INCREASE; DRUG TOLERABILITY; DYSPNEA; EMOTIONAL DISORDER; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HYPOKALEMIA; IRRITABILITY; JUVENILE MYELOMONOCYTIC LEUKEMIA; MALE; MELENA; MONOSOMY 7; MULTIPLE CYCLE TREATMENT; NEUROFIBROMATOSIS; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRENYLATION; PRIORITY JOURNAL; RASH; SPLENECTOMY; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADULT; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENZYMOLOGY; INFANT; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PRESCHOOL CHILD; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYTARABINE; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; ISOTRETINOIN; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MALE; MIDDLE AGED; QUINOLONES; SURVIVAL RATE; VIDARABINE;

EID: 84923225906     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25342     Document Type: Article

References (40)

1. Busque L, Gilliland DG, Prchal JT, Sieff CA, Weinstein HJ, Sokol JM, Belickova M, Wayne AS, Zuckerman KS, Sokol L. Clonality in juvenile chronic myelogenous leukemia. Blood 1995; 85:21-30.
2. Niemeyer CM, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U, Haas O, Harbott J, Hasle H, Kerndrup G, Locatelli F, Mann G, Stollmann-Gibbels B, van't Veer-Korthof ET, van Wering E, Zimmermann M. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood 1997; 89:3534-3543.
3. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991; 77:925-929.
4. Emanuel PD. Juvenile myelomonocytic leukemia. Curr Hematol Rep 2004; 3:203-209.
5. Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, Mullighan CG, Chen L, Bergstraesser E, Bueso-Ramos CE, Emanuel PD, Hasle H, Issa JP, van den Heuvel-Eibrink MM, Locatelli F, Stary J, Trebo M, Wlodarski M, Zecca M, Shannon KM, Niemeyer CM. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009; 114:1859-1863.
6. Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: A report from the 2nd International JMML Symposium; 2009, pp 355-362.
7. Chan HS, Estrov Z, Weitzman SS, Freedman MH. The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia. J Clin Oncol 1987; 5:1960-1967.
8. Festa RS, Shende A, Lanzkowsky P. Juvenile chronic myelocytic leukemia: Experience with intensive combination chemotherapy. Med Pediatr Oncol 1990; 18:311-316.
9. Hasle H, Kerndrup G, Yssing M, Clausen N, Ostergaard E, Jacobsen N, Jacobsen BB. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Leukemia 1996; 10:1269-1273.
10. Lilleyman JS, Harrison JF, Black JA. Treatment of juvenile chronic myeloid leukemia with sequential subcutaneous cytarabine and oral mercaptopurine. Blood 1977; 49:559-562.
11. Bergstraesser E, Hasle H, Rogge T, Fischer A, Zimmermann M, Noellke P, Niemeyer CM. Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: A retrospective analysis and definition of response criteria. Pediatr Blood Cancer 2007; 49:629-633.
12. Locatelli F. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 2005; 105:410-419.
13. Yoshimi A, Mohamed M, Bierings M, Urban C, Korthof E, Zecca M, Sykora K-W, Duffner U, Trebo M, Matthes-Martin S, Sedlacek P, Klingebiel T, Lang P, Führer M, Claviez A, Wössmann W, Pession A, Arvidson J, O'Marcaigh AS, van den Heuvel-Eibrink MM, Stary J, Hasle H, Nollke P, Locatelli F, Niemeyer CM. Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia 2007; 21:556-560.
14. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72:567-572.
15. Emanuel PD, Zuckerman KS, Wimmer R, Cohn S, Chaffee S, Castleberry RP. In vivo 13-cis retinoic acid therapy decreases the in vitro GM-CSF hypersensitivity in juvenile chronic myelogenous leukemia (JCML) [abstract]. Blood 1991; 78:170a.
16. Castleberry RP, Emanuel PD, Zuckerman KS, Cohn S, Strauss L, Byrd RL, Homans A, Chaffee S, Nitschke R, Gualtieri RJ. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med 1994; 331:1680-1684.
17. Castleberry RP, Chang M, Maybee D, Emanuel PD. A phase II study of 13-cis retinoic acid (CRA) in juvenile myelomonocytic leukemia (JMML): A Pediatric Oncology Group (POG) study [abstract]. Blood 1997; 90:346a.
18. Casey PJ, Solski PA, Der CJ, Buss JE. p21ras is modified by a farnesyl isoprenoid. Proc Nati Acad Sci 1989; 86:8323-8327.
19. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001; 61:131-137.
20. Emanuel PD, Snyder RC, Wiley T, Gopurala B, Castleberry RP. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood 2000; 95:639-645.
21. Widemann BC, Arceci RJ, Jayaprakash N, Fox E, Zannikos P, Goodspeed W, Goodwin A, Wright JJ, Blaney SM, Adamson PC, Balis FM. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group. Pediatr Blood Cancer 2011; 56:226-233.
22. Niemeyer C, Fenu S, Hasle H, Mann G, Stary J, van Wering E. Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood 1998; 91:365-367.
23. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial. Blood 2001; 97:3361-3369.
24. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, Lerner KG, Glucksberg H, Buckner CD. Bone-marrow transplantation (second of two parts). N Engl J Med 1975; 292:895-902.
25. Kalra R, Paderanga DC, Olson K, Shannon KM. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood 1994; 84:3435-3439.
26. Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, Cheng JW, Lee CM, Stokoe D, Bonifas JM. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004; 103:2325-2331.
27. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. J Am Med Assoc 1997; 278:51-57.
28. Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, Gillespie A, Whitcomb P, Palumbo JS, Pitney A. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006; 24:507-516.
29. Castleberry RP, Loh ML, Jayaprakash N, Peterson A, Casey V, Chang M, Widemann B, Emanuel PD. Phase II window study of the farnesyltransferase inhibitor R115777 (Zarnestra) in untreated juvenile myelomonocytic leukemia (JMML): A children's oncology group study. Blood 2005; 106:727a-728a.
30. Locatelli F, Niemeyer C, Angelucci E, Bender-Götze C, Burdach S, Ebell W, Friedrich W, Hasle H, Hermann J, Jacobsen N, Klingebiel T, Kremens B, Mann G, Pession A, Peters C, Schmid HJ, Stary J, Suttorp M, Uderzo C, van't Veer-Korthof ET, Vossen J, Zecca M, Zimmermann M. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: A report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol 1997; 15:566-573.
31. Harousseau J-L. Farnesyltransferase inihibitors in hematologic malignancies. Blood reviews 2007; 21:173-182.
32. Braun T, Fenaux P. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 2008; 141:576-586.
33. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3:11-22.
34. Raponi M, Lancet JE, Fan H, Dossey L, Lee G, Gojo I, Feldman EJ, Gotlib J, Morris LE, Greenberg PL, Wright JJ, Harousseau J-L, Lowenberg B, Stone RM, De Porre P, Wang Y, Karp JE. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008; 111:2589-2596.
35. Raponi M, Harousseau J-L, Lancet JE, Lowenberg B, Stone R, Zhang Y, Rackoff W, Wang Y, Atkins D. Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 2007; 13:2254-2260.
36. Biagi C, Astolfi A, Masetti R, Serravalle S, Franzoni M, Chiarini F, Melchionda F, Pession A. Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib. Leukemia 2010; 24:1230-1233.
37. Manabe A, Okamura J, Yumura-Yagi K, Akiyama Y, Sako M, Uchiyama H, Kojima S, Koike K, Saito T, Nakahata T; MDS Committee of the Japanese Society of Pediatric Hematology . Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 2002; 16:645-649.
38. Emanuel PD. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 2008; 22:1335-1342.
39. Hasle H, Baumann I, Bergsträsser E, Fenu S, Fischer A, Kardos G, Kerndrup G, Locatelli F, Rogge T, Schultz KR, Stary J, Trebo M, van den Heuvel-Eibrink MM, Harbott J, Nollke P, Niemeyer CM. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004; 18:2008-2014.
40. Archambeault S, Flores NJ, Yoshimi A, Kratz CP, Reising M, Fischer A, Noellke P, Locatelli F, Sedlacek P, Flotho C, Zecca M, Emanuel PD, Castleberry RP, Niemeyer CM, Bader P, Loh ML. Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. Blood 2008; 111:1124-1127.